Novo CEO sees innovation as a matter of survival amid pipeline setbacks

Summary

Novo Nordisk CEO Maziar Mike Doustdar addressed the company's recent clinical roadblocks during a second quarter earnings call, emphasizing that innovation and failure are inherent to drug development. The Danish pharma is focused on strengthening its pipeline to overcome recent setbacks.